138 related articles for article (PubMed ID: 17638862)
1. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.
Chen N; Ye XC; Chu K; Navone NM; Sage EH; Yu-Lee LY; Logothetis CJ; Lin SH
Cancer Res; 2007 Jul; 67(14):6544-8. PubMed ID: 17638862
[TBL] [Abstract][Full Text] [Related]
2. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Lin SH; Cheng CJ; Lee YC; Ye X; Tsai WW; Kim J; Pasqualini R; Arap W; Navone NM; Tu SM; Hu M; Yu-Lee LY; Logothetis CJ
Oncogene; 2008 Sep; 27(39):5195-203. PubMed ID: 18490922
[TBL] [Abstract][Full Text] [Related]
3. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH; Lee YC; Choueiri MB; Wen S; Mathew P; Ye X; Do KA; Navone NM; Kim J; Tu SM; Yu-Lee LY; Logothetis CJ
Clin Cancer Res; 2008 Jun; 14(12):3729-36. PubMed ID: 18559590
[TBL] [Abstract][Full Text] [Related]
4. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone.
Jacob K; Webber M; Benayahu D; Kleinman HK
Cancer Res; 1999 Sep; 59(17):4453-7. PubMed ID: 10485497
[TBL] [Abstract][Full Text] [Related]
5. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow.
Vakar-Lopez F; Cheng CJ; Kim J; Shi GG; Troncoso P; Tu SM; Yu-Lee LY; Lin SH
J Pathol; 2004 Jun; 203(2):688-95. PubMed ID: 15141384
[TBL] [Abstract][Full Text] [Related]
7. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis.
Koblinski JE; Kaplan-Singer BR; VanOsdol SJ; Wu M; Engbring JA; Wang S; Goldsmith CM; Piper JT; Vostal JG; Harms JF; Welch DR; Kleinman HK
Cancer Res; 2005 Aug; 65(16):7370-7. PubMed ID: 16103089
[TBL] [Abstract][Full Text] [Related]
8. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
[TBL] [Abstract][Full Text] [Related]
9. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.
Cheng CJ; Ye XC; Vakar-Lopez F; Kim J; Tu SM; Chen DT; Navone NM; Yu-Lee LY; Lin SH; Hu MC
Mol Cancer Res; 2007 Jul; 5(7):675-84. PubMed ID: 17634423
[TBL] [Abstract][Full Text] [Related]
10. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.
Mateo F; Meca-Cortés O; Celià-Terrassa T; Fernández Y; Abasolo I; Sánchez-Cid L; Bermudo R; Sagasta A; Rodríguez-Carunchio L; Pons M; Cánovas V; Marín-Aguilera M; Mengual L; Alcaraz A; Schwartz S; Mellado B; Aguilera KY; Brekken R; Fernández PL; Paciucci R; Thomson TM
Mol Cancer; 2014 Oct; 13():237. PubMed ID: 25331979
[TBL] [Abstract][Full Text] [Related]
11. Bone matrix osteonectin limits prostate cancer cell growth and survival.
Kapinas K; Lowther KM; Kessler CB; Tilbury K; Lieberman JR; Tirnauer JS; Campagnola P; Delany AM
Matrix Biol; 2012 Jun; 31(5):299-307. PubMed ID: 22525512
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.
Podgorski I; Linebaugh BE; Koblinski JE; Rudy DL; Herroon MK; Olive MB; Sloane BF
Am J Pathol; 2009 Sep; 175(3):1255-69. PubMed ID: 19700761
[TBL] [Abstract][Full Text] [Related]
13. [Screening of phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1) by cDNA microarray and influence of overexpression of PAG1 on biologic behavior of human metastatic prostatic cancer cell line in vitro].
Yu WJ; Wang YW; Xie ZG; You JF; Wang JL; Cui XL; Pei F; Zheng J
Zhonghua Bing Li Xue Za Zhi; 2010 Feb; 39(2):88-94. PubMed ID: 20388373
[TBL] [Abstract][Full Text] [Related]
14. Behavior of prostate cancer cells in a nanohydroxyapatite/collagen bone scaffold.
Cruz-Neves S; Ribeiro N; Graça I; Jerónimo C; Sousa SR; Monteiro FJ
J Biomed Mater Res A; 2017 Jul; 105(7):2035-2046. PubMed ID: 28371333
[TBL] [Abstract][Full Text] [Related]
15. PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo.
Cumming AP; Hopmans SN; Vukmirović-Popović S; Duivenvoorden WC
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):286-94. PubMed ID: 21826098
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathway for cancer metastasis to bone.
De S; Chen J; Narizhneva NV; Heston W; Brainard J; Sage EH; Byzova TV
J Biol Chem; 2003 Oct; 278(40):39044-50. PubMed ID: 12885781
[TBL] [Abstract][Full Text] [Related]
17. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.
Wong SY; Crowley D; Bronson RT; Hynes RO
Clin Exp Metastasis; 2008; 25(2):109-18. PubMed ID: 18058030
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
19. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis.
Hsieh SY; He JR; Yu MC; Lee WC; Chen TC; Lo SJ; Bera R; Sung CM; Chiu CT
J Proteome Res; 2011 Oct; 10(10):4715-24. PubMed ID: 21877752
[TBL] [Abstract][Full Text] [Related]
20. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment.
Reichert JC; Quent VM; Burke LJ; Stansfield SH; Clements JA; Hutmacher DW
Biomaterials; 2010 Nov; 31(31):7928-36. PubMed ID: 20688384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]